Ashe Gena L
Ashe Gena L, CLO, CS, reported an open-market or private sale at Anterix Inc. involving 293.000000 shares for an estimated $25033.92. Reported holdings after the transaction were 9238.000000 shares. A 10b5-1 reference was not detected in the stored filing text.
- Trade date
- Sep 08, 2026
- Filing date
- Sep 11, 2026
How reported position traded is calculated
Shares sold ÷ (holdings after + shares sold). Estimated position before: 9,531 shares.
Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.
Filing warnings
Notes recorded with this filingATEX price since this filing
Daily closing prices, with the filing date and available return windowsTransaction facts
Stored Form 4 columns with their raw values
- Type
- Sell Code S
- Identifier
- 0001669943-26-000021 Common Stock
- Transaction date
- Sep 08, 2026 Filed Sep 11, 2026, 08:08 PM · 3d delay
- Shares
- 293 sh $85.44 per share
- Estimated value
- -$25.0k Computed from shares × price
- Holdings after
- 9,238 sh Direct
Filing signal explanations
Badges describe filing facts only — not predictions.
0 points
Compact filing score computed from stored Form 4 facts. Version v1.
This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.
How this score is calculated
- direct_ownership+6 points
direct_or_indirect_ownership = D
Direct ownership reports the insider's personal stake. - amended_filing-6 points
is_amendment = true
Amended filing: the original transaction may have been restated.
Signed filing-only points, not a probability or expected return. Version v1.
Reported relationships & other filings
Form 4 relationship flags and nearby filing context
Chief Legal Officer & Corp Sec
- F1
The Reporting Person exercised a stock option to purchase 6,833 shares of the Issuer's Common Stock for $34.96 per share and paid the exercise price on a cashless basis, resulting in the Issuer withho…
- F2
The option shares subject to this option shall vest and become exercisable in three equal annual installments, with 1/3 of the option shares vesting and becoming exercisable on May 20, 2026, and with…
0 other transactions
0 recent txs